Treatment of Lichen Planus

Cribier, B.; Françès, Camille; Chosidow, Olivier

doi:10.1001/archderm.134.12.1521

Cited by 172 publications

(17 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Application of ultra-high potency corticosteroid is the mainstay of therapy, whereas topical calcineurin ointments also have efficacy [48,49,51–55]. The anti-inflammatory antibiotic clindamycin has been used successfully as an intravaginal therapy, often applied together with corticosteroids [56].…”

Section: Genitaliamentioning

confidence: 99%

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report

Carpenter

Kitko

Sharon

et al. 2015

Biology of Blood and Marrow Transplantation

193

204

View full text Add to dashboard Cite

The 2006 National Institutes of Health (NIH) Consensus paper presented recommendations by the Ancillary Therapy and Supportive Care Working Group to support clinical research trials in chronic graft-versus-host disease (GVHD). Topics covered in that inaugural effort included the prevention and management of infections and common complications of chronic GVHD, as well as recommendations for patient education and appropriate follow-up. Given the new literature that has emerged during the past 8 years, we made further organ-specific refinements to these guidelines. Minimum frequencies are suggested for monitoring key parameters relevant to chronic GVHD during systemic immunosuppressive therapy and, thereafter, referral to existing late effects consensus guidelines is advised. Using the framework of the prior consensus, the 2014 NIH recommendations are organized by organ or other relevant systems and graded according to the strength and quality of supporting evidence.

show abstract

Section: Genitaliamentioning

confidence: 99%

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report

Carpenter

Kitko

Sharon

et al. 2015

Biology of Blood and Marrow Transplantation

193

204

View full text Add to dashboard Cite

show abstract

“…Oral acitretin has been shown to be effective [64]. Many other treatments are used, including mycophenolate mofetil, which efficacy is uncertain, and sulfasalazine in patients with generalized lichen planus [65].…”

Section: Lichen Planus In Lementioning

confidence: 99%

Cutaneous Manifestations of Systemic Lupus Erythematosus

Uva

Miguel

Pinheiro

et al. 2012

Autoimmune Diseases

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease of unknown etiology with many clinical manifestations. The skin is one of the target organs most variably affected by the disease. The American College of Rheumatology (ACR) established 11 criteria as a classificatory instrument to operationalise the definition of SLE in clinical trials. They were not intended to be used to diagnose individuals and do not do well in that capacity. Cutaneous lesions account for four of these 11 revised criteria of SLE. Skin lesions in patients with lupus may be specific or nonspecific. This paper covers the SLE-specific cutaneous changes: malar rash, discoid rash, photosensitivity, and oral mucosal lesions as well as SLE nonspecific skin manifestations, their pathophysiology, and management. A deeper thorough understanding of the cutaneous manifestations of SLE is essential for diagnosis, prognosis, and efficient management. Thus, dermatologists should cooperate with other specialties to provide optimal care of SLE patient.

show abstract

“…Treatment of erosive lichen planus is complicated and there is as yet no treatment available that cures the disease completely 6,7 . There are no large randomized clinical trials on treatment of this disease 9 . Corticosteroids locally and/or orally are the most frequently used treatment 2,10,11 .…”

Section: Introductionmentioning

confidence: 99%